Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).
PS-3.04: Innovation in the health sector: challenges and opportunities for inclusiveness and sustainability 2
10:30am - 12:00pm
Session Chair: Marcela Suárez Estrada, Freie Universität Berlin Discussant: Dinesh Abrol, Institute for Studies in Industrial Development
Location:Savoy Room-4 (Homann)
Innovation and Public Procurement in the Health Sector in Brazil: a preliminary analysis of the Partnership for Productive Development (PDPs) program
Marco Antonio Vargas1, Jorge Britto1, Marina Szapiro2
1Universidade Federal Fluminense, Brazil; 2Universidade Federal do Rio de Janeiro
The paper analyzes a relevant Brazilian experience related to an attempt to promote innovation and to increase access to essential drugs in the Health National System through Public Procurement and Regulation policies. The focus of the paper relies on a major program coordinated by the Ministry of Health entitled Partnerships for Productive Development (Parceiras para o Desenvolvimento Produtivo – PDPs). This program was launched in 2009 and has become one of the backbones of the articulation between the Health Policy and Innovation Policy for the Brazilian Health Economic and Industrial Complex (HIC), by providing means for technology transfer processes between public and private pharmaceutical laboratories.
The Tale of Three Technologies : Examining Inequality in Health Research in India
Rajesh Kalarivayil1,2, Pranav N. Desai2
1Tezpur University, India; 2Jawaharlal Nehru University, India
The paper analyses multiple dimensions of inequalities in cancer research in emerging technologies. Analysing biotechnology, nanotechnology and bioinformatics in cancer research the paper explores the inequality in health research in emerging technologies in India. Firstly the paper investigates inequality in health research as result of advancement in technological platforms like biotechnology, nanotechnology and bioinformatics leading to exclusion of cancers affecting poor population. Secondly the paper analyses inequality in health research resulting from exclusion of certain technology platforms like bioinformatics and biosimilars and its implications for equity in health research. Finally the paper analyses science technology and innovation polices in the area of biotechnology, nanotechnology and bioinformatics to explore the pathways of inequality in science technology and innovation policies in India. Empirical analysis is performed on a unique data set of publications and clinincal trials related to oncological research. Interview with selected experts and analysis of government doccuments are also used for analysis. The analysis of data draws attention to inequalities in health research at multiple levels. The development of technologies like nanomedicine, gneomics and biomarkers has resulted in the exclusion of certain forms of cancers prevalent among poor people indicating inequality in research within technological platforms. The paper also shows that there is inequality in research between different technological platforms like biotechnology, nanomedicine and bioinformatics. This form of inequality stems mainly from policies that do not promote production of innovation relevant knowledge and that does not foster learning through problem solving. The paper also provides an overview of the issues plaguing the policy arena of emerging technologies like biotechnology, nanotechnology and bioinformatics. The data presented in the paper shows that the policies, schemes and programmes of the government are weak in addressing critical areas like fostering entrepreneurship, promoting translational research, developing infrastructure for cutting edge research, instituting testing labs for regulatory studies and establishing adequate regulatory mechanisms. The data also shows that lack of support from government has lead to the trailing of technology platforms like bioinformatics, in which the country had achieved considerable progress.
Building Capacity For Innovation Through R&D Consortia In Health Projects: From Network Interaction To Systemic Transformation
Ria Hardiyati, Trina Fizzanty, Erman Aminullah
Indonesian Institute of Sciences (LIPI), Indonesia
This paper attempt to elucidate the postulation that there is a continuous trajectory from the network interaction in scientific research towards the systemic transformation in innovation capacity building. This study will expose that the availability of research capacity in certain areas can be developed into innovation capacity through R&D consortia, where building research capacity is a long term process of scientific accumulation. This study utilizes two techniques: i. scientometrics by using data set on scientific publication as indicator of building research capacity, and: ii. case study of R&D consortia in stem cell and vaccine research in understanding innovation capacity.
Innovation capacity-building is still underway in the current Indonesian development. Enhancing capacity-building by intensifying R&D consortia is still a big challenge for Indonesia. Indonesia has the capacity to engage in life science R&D, especially in the sectors of health. Improvements in innovation capacity have geared towards life science–based technology innovation. Current initiatives to enhance innovation capacity in Indonesia exist by intensifying R&D consortia in life science, especially in vaccine and stem cell research. In vaccine research, R&D agency for Ministry of Health has the best centrality measures in institution social network. Whereas on stem cell research, top ten institution with the best centrality measures is not only dominated by state university but also universities from eastern Indonesia or private university.
The research capacity in the area of vaccines has been long started from individual research conducted by researcher. It has been continued into organization research managed by university and research institution, and then vaccine research has been developed into building innovation capacity through R&D consortia. However, in the areas of stem cell there is still lack of evidence that individual research capacity has been continued into organization research managed by university and research institution but it directly leap to build innovation capacity through R&D consortia. It is therefore further empirical evidence is needed to support continuous trajectory from the network interaction in scientific research towards the systemic transformation in innovation capacity building.